8-K
filed May 1, 2026, 7:59 PM ET
ticker CUE
CIK 0001645460
M&A
confidence high
sentiment neutral
materiality 0.85
Cue Biopharma licenses ex-China rights to anti-IgE mAb Ascendant-221; raises $30M; appoints new CEO
Cue Biopharma, Inc.
- License with Ascendant Health Sciences: $15M upfront, up to $676.5M milestones, tiered high-single-to-low-double-digit royalties on ex-China sales.
- Concurrent private placement raises ~$28M net via pre-funded warrants and warrants at $11.00/unit to accredited investors including new CEO.
- New CEO Dr. Shao-Lee Lin appointed; participates in the private placement.
- Ascendant receives pre-funded warrants for 551,724 shares at $0.001; total potential dilution from warrants exceeds 4.6M shares.
- Company to seek stockholder approval for share issuances under Nasdaq rules; special meeting within 90 days.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Cue Biopharma, Inc. issued up to 551,724 shares of common stock of warrant to Ascendant Health Sciences Ltd..
- Security
- warrant
- Shares
- up to 551,724 shares of common stock
- Purchaser
- Ascendant Health Sciences Ltd.
Exact text from the filing
the Company agreed to issue to the Licensor at an initial closing (the “Initial Closing”) pre-funded warrants (the “Initial Closing Pre-Funded Warrants”) to purchase up to 551,724 shares of common stock, $0.001 par value per share, of the Company (the “Common Stock”), as partial consideration for the license and rights granted under the License Agreement.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Shao-Lee Lin was appointed as Member of the Board at Cue Biopharma, Inc..
- Action
- appointed
- Role
- Member of the Board
Exact text from the filing
On April 27, 2026, the Board appointed Dr. Shao-Lee Lin as the Company’s President and Chief Executive Officer and as a member of the Board, effective as of her commencement of employment with the Company, which began on April 30, 2026
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Shao-Lee Lin was appointed as President and Chief Executive Officer at Cue Biopharma, Inc..
- Action
- appointed
- Role
- President and Chief Executive Officer
Exact text from the filing
On April 27, 2026, the Board appointed Dr. Shao-Lee Lin as the Company’s President and Chief Executive Officer and as a member of the Board, effective as of her commencement of employment with the Company, which began on April 30, 2026
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Lucinda Warren resigned as Interim President and Chief Executive Officer at Cue Biopharma, Inc..
- Action
- resigned
- Role
- Interim President and Chief Executive Officer
Exact text from the filing
Dr. Lin will succeed Lucinda Warren whose resignation as Interim President and Chief Executive Officer was effective as of April 30, 2026
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Cue Biopharma, Inc. entered into License Agreement with Ascendant Health Sciences Ltd. valued at $15.0 million as the upfront payment, up to an aggregate of $676.5 million in additional potential m (effective 2026-04-30).
- Action
- entry
- Agreement
- license
- Counterparty
- Ascendant Health Sciences Ltd.
- Value
- $15.0 million as the upfront payment, up to an aggregate of $676.5 million in additional potential m
- Effective
- 2026-04-30
Exact text from the filing
On April 30, 2026, Cue Biopharma, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Ascendant Health Sciences Ltd., a Cayman Limited Company (the “Licensor”).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.